Lab Results Support Advancing QRL-201 to Clinical Trial

Lab Results Support Advancing QRL-201 to Clinical Trial

315516

Lab Results Support Advancing QRL-201 to Clinical Trial

An investigational antisense oligonucleotide (ASO) molecule that works by increasing the production of Stathmin-2 protein effectively reversed a number of neurodegenerative processes in lab-grown motor neurons, the cells that are damaged in amyotrophic lateral sclerosis (ALS), a study found. The rescue occurred even in the absence of TDP-43, a protein that controls the levels of Stathmin-2 in cells, and translated into healthier motor neurons with more and longer neurites. A neurite is a projection that…

You must be logged in to read/download the full post.